Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ
Closed
Oct 23, 2026
Day's Range
5.0152 wk Range
5.01Overview - PHAT - Phathom Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
946.36M
P/E (Trailing)
-2.31
P/E (Forward)
6.49
PEG Ratio
0.02
Price / Sales (TTM)
2.36
Price / Book
-1.70
EV / EBITDA
-23.58
Profitability
Gross Margin
79.67%
Profit Margin
-41.33%
Operating Margin
-5.33%
Return on Assets
-8.80%
Return on Equity
50.49%
Ownership
Shares Outstanding
80.07M
Float
65.07M
Short % of Shares Outstanding
13.14%
Held by Insiders
4.64%
Held by Institutions
92.30%
Price stats
Beta
0.50
50-Day Avg
8.26
200-Day Avg
11.11
Analyst Consensus
12 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - PHAT - Phathom Pharmaceuticals, Inc.
Peers - PHAT - Phathom Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- PHATNASDAQPhathom Pharmaceuticals, Inc.566.30MMarket Cap-92.14%52-week change-2.31P/E (Trailing)-41.33%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - PHAT - Phathom Pharmaceuticals, Inc.
About
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
